CD274 and neoplasm: In another discovery, Ding et al. reported that the diabetes drug canagliflozin disrupts the interaction between SGLT2 and PD-L1, allowing PD-L1 recognition and degradation by the Cullin 3-spopoe3 ligase and enhancing T-cell attack on tumor cells [48].